FDA panel endorses broader peptide use at compounding pharmacies

An FDA advisory panel voted to endorse broader use of peptides at lightly regulated compounding pharmacies, which have grown into a multibillion-dollar industry. The decision has raised concerns among experts about an uncontrolled boom in peptide prescribing. Critics warn that loose oversight of compounding pharmacies poses significant risks to patients.